Novo Nordisk公司向TUL公司发放肥胖症和糖尿病药物UBT251许可证,最高可达20亿美元。 Novo Nordisk licenses obesity and diabetes drug UBT251 from TUL for up to $2 billion.

Novo Nordisk已经与联合实验室国际控股有限公司(TUL)就UBT251签署了独家许可证协议,这是治疗肥胖症和2型糖尿病的早期研制药物。 Novo Nordisk has entered an exclusive license agreement with United Laboratories International Holdings Limited (TUL) for UBT251, a drug in early-stage development for treating obesity and type 2 diabetes. Novo Nordisk公司除了中国和领土以外,还取得了世界范围的权利,TUL公司收到2亿美元的预付付款、可能达到18亿美元的里程碑付款和特许使用费。 Novo Nordisk gains worldwide rights, except for China and territories, with TUL receiving a $200 million upfront payment, potential milestone payments of up to $1.8 billion, and royalties. UBT251在早期肥胖症治疗试验中显示出有希望的成果。 UBT251 has shown promising results in early trials for obesity treatment.